20090-69-1

Basic information

• Product Name: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)
• Synonyms: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI);5-Amino-2-chloro-4-methylpyrimidine;2-chloro-4-methyl-pyrimidin-5-ylamine;2-Chloro-4-MethylpyriMidin-5-aMine;NSC 243816;5-PyriMidinaMine, 2-chloro-4-Methyl-
• CAS NO: 20090-69-1
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.57424
• Product Categories: PYRIMIDINE
• Mol File: 20090-69-1.mol

Chemical Properties

• Melting Point: 93.5℃
• Boiling Point: 309.4 °C at 760 mmHg
• Flash Point: 140.9 °C
• Appearance: /
• Density: 1.349 g/cm³
• Vapor Pressure: 0.00064mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.36±0.29(Predicted)
• CAS DataBase Reference: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(20090-69-1)
• EPA Substance Registry System: 5-Pyrimidinamine, 2-chloro-4-methyl- (9CI)(20090-69-1)

Safety Data

• Hazardous Substances Data: 20090-69-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Pyrimidinamine, 2-chloro-4-methyl(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in the development of anti-cancer, anti-inflammatory, and anti-viral drugs. Its unique structure allows it to be a versatile building block in medicinal chemistry.
Used in Agrochemical Industry:
In the agrochemical sector, 5-Pyrimidinamine, 2-chloro-4-methyl(9CI) is utilized as a component in the formulation of agrochemicals, contributing to the development of effective and targeted pest control solutions.
Used in Organic Compounds Production:
5-Pyrimidinamine, 2-chloro-4-methyl(9CI) is used as a building block in the production of a variety of organic compounds, highlighting its importance in organic synthesis and the creation of new chemical entities.
Used in Research and Development:
5-Pyrimidinamine, 2-chloro-4-methyl(9CI) serves as a research tool in both chemical and biological studies, aiding scientists in understanding the mechanisms of action and potential applications of pyrimidine-based compounds.

InChI:InChI=1/C5H6ClN3/c1-3-4(7)2-8-5(6)9-3/h2H,7H2,1H3

Upstream product

• 13162-26-0 2,4-dichloro-6-methyl-5-nitropyrimidine 
• 16632-21-6 5-nitro-6-methyluracil 
• 626-48-2 6-Methyluracil 
• 13162-27-1 5-amino-2,4-dichloro-6-methylpyrimidine 
• 7732-18-5 water 

Downstream Products

• 908099-97-8 2-methoxy-4-methylpyrimidin-5-amine 
• 847139-63-3 4-methyl-2-methylsulfanyl-pyrimidin-5-ylamine 
• 3438-61-7 5-amino-4-methylpyrimidine 
• 89181-77-1 4-methylpyrimidine-2,5-diamine 
• 633328-96-8 N-(2-chloro-4-methylpyrimidin-5-yl)acetamide 
• 1393181-01-5 5-chloro-1-methyl-1H-pyrazolo[4,3-d]pyrimidine 
• 633328-98-0 5-chloro-1H-pyrazolo[4,3-d]pyrimidine 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Ethanol compound used as FGFR inhibitor

The invention discloses an ethanol compound used as a FGFR inhibitor. The invention provides the compound as shown in a formula I which is described in the specification or a pharmaceutically acceptable salt thereof, a preparation method for the compound and application of the compound as a medicine to treatment of cancers.

Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors

The invention relates to pyridopyrimidinone compounds according to formula (I), wherein the substituents and symbols are as defined in the description. The compounds are inhibitors of Plk1.

ORTHO PYRROLIDINE, BENZYL-SUBSTITUTED HETEROCYCLE CCR1 ANTAGONISTS FOR AUTOIMMUNE DISEASES and INFLAMMATION

Compounds of the formula are disclosed. The compounds are CCR1 antagonists which are useful for the treatment and prevention of inflammatory and autoimmune diseases. Other embodiments are also disclosed.